624720-35-0 Usage
Ethyl ester derivative
1H-Indazole-1-acetic acid, 6-amino-, ethyl ester is an ethyl ester derivative of 1H-Indazole-1-acetic acid, meaning it has an ethyl group attached to the acid portion of the molecule.
Indazole-based compound
The compound is based on the indazole structure, which is a five-membered aromatic heterocyclic ring system containing three nitrogen atoms.
Pharmaceutical research and development potential
1H-Indazole-1-acetic acid, 6-amino-, ethyl ester has potential for use in pharmaceutical research and development due to its possible medicinal properties.
Further studies needed
Additional research may be required to fully understand the potential applications and effects of this chemical compound.
Check Digit Verification of cas no
The CAS Registry Mumber 624720-35-0 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 6,2,4,7,2 and 0 respectively; the second part has 2 digits, 3 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 624720-35:
(8*6)+(7*2)+(6*4)+(5*7)+(4*2)+(3*0)+(2*3)+(1*5)=140
140 % 10 = 0
So 624720-35-0 is a valid CAS Registry Number.
624720-35-0Relevant academic research and scientific papers
Design and synthesis of heterocyclic hydroxamic acid derivatives as inhibitors of Helicobacter pylori urease
Muri, Estela Maris F.,Mishra, Hetal,Avery, Mitchell A.,Williamson, John S.
, p. 1977 - 1995 (2007/10/03)
Helicobacter pylori produces ammonia to help counter the acidic environment in the human stomach. The production of ammonia, essential for the microorganism's survival and virulence, is the product of enzymatic conversion of urea by the H. pylori's urease. Inhibition of urease activity by dipeptide hydroxamic acids has previously been demonstrated using a variety of fluorides, thiols and hydroxamic acids. Studies employing computer-aided drug design techniques have been utilized to suggest a novel series of heterocyclic hydroxamic acid derivatives as potential as urease inhibitors. The heterocyclic compounds 7a,b, 10b, 12b, 16b, and 19b have been designed, synthesized, and preliminarily tested as dipeptide mimics which offer a structure that is more biologically stable than that of the reported dipeptide inhibitors.
